Securities.io maintains rigorous editorial standards and may receive compensation from reviewed links. We are not a registered investment adviser and this is not investment advice. Please view our ...

A U.S. appeals court has upheld a temporary restraining order that prevents OpenAI and Jony Ive's new hardware venture from using the name "io" for products similar to those planned by AI audio ...

IO-Link uses standard unshielded cables to enable real-time data exchange between sensors, actuators and control systems, replacing simple on/off signals with detailed device performance and ...

US border patrol is asking companies to submit plans to turn standard 4x4 trucks into AI-powered watchtowers—combining radar, cameras, and autonomous tracking to extend surveillance on demand. The US ...

Two malicious packages with nearly 8,500 downloads in Rust's official crate repository scanned developers' systems to steal cryptocurrency private keys and other secrets. Rust crates are distributed ...

Apple announced a big change to how it names its operating systems at WWDC 2025 on Monday. Instead of using system names like iOS 19 and macOS 19, the company will now use the year as part of the name ...

Even the minimum requirements feel quite high. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. This is likely tied to the fact that MindsEye is ...

Jony Ive will take on a new role at OpenAI after his firm, IO, was acquired for $6.5 billion. Thomas is a native of upstate New York and a graduate of the University at Albany. As a former member of ...

Cybersecurity researchers have demonstrated a proof-of-concept (PoC) rootkit dubbed Curing that leverages a Linux asynchronous I/O mechanism called io_uring to bypass traditional system call ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a crossroads, with experts highlighting novel targets, combinations and pre-emptive ...